PMID- 33602190
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Feb 18
TI  - Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated 
      patients with type 2 diabetes.
PG  - 25
LID - 10.1186/s12902-021-00690-0 [doi]
LID - 25
AB  - BACKGROUND: In insulin-treated patients with type 2 diabetes mellitus (T2DM), 
      glycemic control is usually suboptimal. METHODS: This study compared the risks of 
      mortality and cardiovascular events in insulin-treated patients adding or not 
      adding alpha-glucosidase inhibitors (AGIs). RESULTS: This cohort study included 
      data from the Taiwan National Health Insurance Research Database. In total, 
      17,417 patients newly diagnosed as having T2DM and undergoing insulin therapy 
      during 2000-2012 were enrolled. Overall incidence rates of all-cause mortality, 
      hospitalized coronary artery disease (CAD), stroke, and heart failure were 
      compared between 4165 AGI users and 4165 matched nonusers. The incidence rates of 
      all-cause mortality were 17.10 and 19.61 per 1000 person-years in AGI nonusers 
      and users, respectively. Compared with nonusers, AGI users had a higher mortality 
      risk [adjusted hazard ratio (aHR) = 1.21, 95% confidence interval 
      (CI) = 1.05-1.40; p = 0.01]. Regarding AGI use, aHRs (95% CI) for cardiovascular 
      death, non-cardiovascular death, hospitalized CAD, stroke, and heart failure were 
      1.20 (0.83-1.74), 1.27 (1.07-1.50), 1.12 (0.95-1.31), 0.98 (0.85-1.14), and 1.03 
      (0.87-1.22) respectively. CONCLUSION: AGI use was associated with higher risks of 
      all-cause mortality and non-cardiovascular death in insulin-treated patients with 
      T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate.
FAU - Yen, Fu-Shun
AU  - Yen FS
AUID- ORCID: 0000-0002-4677-2415
AD  - Dr. Yen's Clinic, No. 15, Shanying Road, Gueishan District, Taoyuan, 33354, 
      Taiwan.
FAU - Wei, James Cheng-Chung
AU  - Wei JC
AD  - Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. 
      Rd., South District, Taichung City, 40201, Taiwan.
AD  - Department of Medicine, Chung Shan Medical University Hospital, No. 110, Sec. 1, 
      Jianguo N. Rd., South District, Taichung City, 40201, Taiwan.
AD  - Graduate Institute of Integrated Medicine, China Medical University, No.91, 
      Hsueh-Shih Road, Taichung, 40402, Taiwan.
FAU - Lin, Mei-Chen
AU  - Lin MC
AD  - Management Office for Health Data, China Medical University Hospital, 3F., 
      No.373-2, Jianxing Road, Taichung, 40459, Taiwan.
AD  - College of Medicine, China Medical University, No. 110, Sec. 1, Jianguo N. Rd., 
      South District, Taichung City, 40201, Taiwan.
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
AUID- ORCID: 0000-0003-4563-4341
AD  - Institute of Population Health Sciences, National Health Research Institutes, 
      No.35, Keyan Rd., Zhunan Township, Miaoli, 35053, Taiwan. cch@nhri.edu.tw.
AD  - Department of Health Services Administration, China Medical University, No.91, 
      Hsueh-Shih Road, Taichung, 40402, Taiwan. cch@nhri.edu.tw.
AD  - Department of Family Medicine, Min-Sheng General Hospital, 168 ChingKuo Road, 
      Taoyuan, 33044, Taiwan. cch@nhri.edu.tw.
FAU - Hwu, Chii-Min
AU  - Hwu CM
AUID- ORCID: 0000-0002-8209-9627
AD  - Faculty of Medicine, National Yang-Ming University School of Medicine, No. 201, 
      Sec. 2 Shi-Pai Rd., Chung-Cheng Build. 11F Room 522, Taipei, 112, Taiwan. 
      chhwu@vghtpe.gov.tw.
AD  - Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans 
      General Hospital, No. 201, Sec. 2 Shi-Pai Rd., Chung-Cheng Build. 11F Room 522, 
      Taipei, 112, Taiwan. chhwu@vghtpe.gov.tw.
LA  - eng
PT  - Journal Article
DEP - 20210218
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Glycoside Hydrolase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycoside Hydrolase Inhibitors/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
PMC - PMC7890630
OTO - NOTNLM
OT  - All-cause mortality
OT  - Alpha-glucosidase inhibitors
OT  - Cardiovascular death
OT  - Coronary artery disease
OT  - Insulin
COIS- The authors that they have no competing interests.
EDAT- 2021/02/20 06:00
MHDA- 2021/11/03 06:00
PMCR- 2021/02/18
CRDT- 2021/02/19 05:40
PHST- 2020/10/23 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/02/19 05:40 [entrez]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/02/18 00:00 [pmc-release]
AID - 10.1186/s12902-021-00690-0 [pii]
AID - 690 [pii]
AID - 10.1186/s12902-021-00690-0 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2021 Feb 18;21(1):25. doi: 10.1186/s12902-021-00690-0.